Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. — Dimitrios Pectasides (2003) | RDL Network
Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
Despite the general consensus that ciplatin-based chemotherapy is superior to carboplatin-containing regimens in testicular cancer, 2 cycles of CEB90 may be an equally effective treatment option as adjuvant therapy for high-risk clinical stage I and IM patients.
Dimitrios Pectasides, T. Economopoulos, G. Kouvatseas, A. Antoniou, Z. Zoumbos, Gerasimos Aravantinos, C. Tsatalas, A. Halikia, C. Nikolaides, Christos Kiamouris, Eleni Pappa, N. Pavlidis, D. Skarlos, George Fountzilas, Meletios A Dimopoulos
David Pryor, Mathias Bressel, Nathan Lawrentschuk, Ben Tran, Jennifer Mooi, Jeremy Lewin, Arun Azad, Duncan Colyer, Nitika Neha, Mark Shaw, Sarat Chander, Paul J. Neeson, Daniel Moon, Katharine Cuff, Simon Wood, Declan G. Murphy, Shahneen Sandhu, Sherene Loi, Shankar Siva
Discussion(0)
No comments yet. Be the first to comment.